Hepcidin and Anaemia in Pregnancy (HAPn)

Conditions

Anaemia in pregnancy Pregnancy and Childbirth

Bah A, Muhammad AK, Wegmuller R, Verhoef H, Goheen MM, Sanyang S, Danso E, Sise EA, Pasricha SR, Armitage AE, Drakesmith H, Cross JH, Moore SE, Cerami C, Prentice AM.

2019-11-0124 citations

10.1016/s2214-109x(19)30393-6

A double blind randomised controlled trial comparing standard dose of iron supplementation for pregnant women with two screen-and-treat approaches using hepcidin as a biomarker for ready and safe to receive iron.

Bah A, Wegmuller R, Cerami C, Kendall L, Pasricha SR, Moore SE, Prentice AM.

2016-07-1315 citations

10.1186/s12884-016-0934-8

Interventions

This study will involve 462 pregnant women between 14 and 22 weeks gestation over a period of 12 weeks randomly assigned (1:1:1 ratio) to either receive: 1. UNIMMAP containing 60 mg/da

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Pregnant (gestational age between 14 - 22 weeks) 2. Age: 18 to 45 years 3. Likely to be resident in study area for duration of trial 4. Written informed consent obtained

Exclusion criteria

Exclusion criteria: 1. Severely anaemic (< 7 g/dl) 2. Seriously ill (infectious disease of clinical significance) at recruitment 3. Chronic disease 4. Pregnancy complications (e.g. pre-eclampsia) at enrolment 5. Already part of another study

Design outcomes

Primary

Measure	Time frame
Haemoglobin - defined as pregnancy stage adjusted haemoglobin at day 84	—

Secondary

Measure	Time frame
1. Proportion of anaemia (Hb < 11 g/dl) at day 84 2. Iron deficiency prevalence at day 84 3. Iron deficiency anaemia (IDA) prevalence at day 84 4. Iron dosage 5. Beneficial and adverse events 6. Compliance	—

Countries

Gambia

Outcome results

None listed